Tolcapone: An Efficacy and Safety Review (2007)

@article{Olanow2007TolcaponeAE,
  title={Tolcapone: An Efficacy and Safety Review (2007)},
  author={C. Olanow and P. Watkins},
  journal={Clinical Neuropharmacology},
  year={2007},
  volume={30},
  pages={287-294}
}
Tolcapone (Tasmar), an inhibitor of catechol-O-methyltransferase, is an effective antiparkinsonian agent when used as an adjunct to levodopa in patients with Parkinson disease who have end-of-dose motor fluctuations. In clinical trials, tolcapone significantly reduced "off" time and levodopa requirements. The drug is generally well tolerated, with the most common adverse events being dopaminergic related. However, clinical trials demonstrated dose-related increases in liver enzymes, and… Expand
Current status of symptomatic medical therapy in Parkinson’s disease
  • S. Factor
  • Psychology, Medicine
  • Neurotherapeutics
  • 2011
Treatment of levodopa‐induced motor complications
Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights
  • Jack J. Chen
  • Medicine
  • The International journal of neuroscience
  • 2011
Levodopa: Past, Present, and Future
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Tolcapone and Hepatotoxic Effects
Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects
Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
...
1
2
3
4
...